Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
WATERTOWN, Mass., Nov. 07, 2016 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 3:00 p.m. Eastern Time at the Lotte New York Palace Hotel in New York City.
A live audio webcast of the Stifel presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 212-600-1902 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected]
